IRIX · XBRL financial data

Iridex financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IRIX's year ends in early January)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Revenue from contracts with customers	12,850	12,458*	11,761	12,631	11,581	12,696*	11,896	13,571	12,484	14,724*	11,799	12,566
Cost of revenue	7,229	7,573*	7,303	7,496	7,258	7,110*	6,841	8,889	8,471	9,247*	7,058	8,270
Gross profit	5,621	4,885*	4,458	5,135	4,323	5,586*	5,055	4,682	4,013	5,477*	4,741	4,296
Research and development	1,541	1,694*	1,536	1,501	1,299	1,113*	876	871	972	949*	905	936
General and administrative	1,945	2,405*	2,468	2,785	2,248	2,275*	1,931	2,216	1,795	1,792*	1,623	1,842
Total operating expenses	7,309	7,966*	7,751	7,773	6,193	6,088*	5,260	5,622	5,424	5,492*	5,065	5,325
Operating income (loss)	(1,688)	(3,081)*	(3,293)	(2,638)	(1,870)	(502)*	(205)	(940)	(1,411)	(15)*	(324)	(1,029)
Interest expense	—	—	—	—	58	88*	—	—	—	year only	—	—
Income tax expense (benefit)	8	60*	38	19	17	(6)*	12	21	4	20*	58	70
Net income (loss)	(1,754)	(2,960)*	(3,464)	(2,679)	(1,933)	(834)*	(1,686)	(994)	(1,573)	(184)*	(524)	(1,266)
Earnings per share, basic USD per share	(0.11)	(0.18)*	(0.21)	(0.16)	(0.12)	(0.05)*	(0.10)	(0.06)	(0.09)	(0.01)*	(0.03)	(0.07)
Earnings per share, diluted USD per share	(0.11)	(0.18)*	(0.21)	(0.16)	(0.12)	(0.05)*	(0.10)	(0.06)	(0.09)	(0.01)*	(0.03)	(0.07)
Weighted average shares, basic thousands of shares	16,231	16,244*	16,253	16,287	16,581	16,635*	16,727	16,793	17,009	17,188*	17,311	17,418
Weighted average shares, diluted thousands of shares	16,231	16,244*	16,253	16,287	16,581	16,635*	16,727	16,793	17,009	17,188*	17,311	17,418

Balance sheet

CSV

Fiscal quarters (IRIX's year ends in early January)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Cash and cash equivalents	7,981	7,034	5,419	4,111	3,860	2,387	7,244	6,778	5,573	6,028	4,595	4,680
Accounts receivable	6,109	6,727	6,525	6,269	5,954	5,951	6,680	7,137	7,132	7,613	6,844	5,674
Inventory	10,118	9,906	11,003	11,124	10,942	10,817	10,142	8,435	7,301	7,877	9,325	9,752
Prepaid and other current assets	1,129	856	2,010	1,730	1,755	1,964	2,357	1,625	1,662	1,802	2,248	2,437
Total current assets	27,342	27,450	27,578	25,007	24,337	23,562	29,129	26,868	24,066	25,252	24,584	23,958
Property and equipment, net	524	351	265	209	157	115	75	40	23	58	139	182
Right-of-use asset	2,789	2,632	2,402	2,172	2,034	1,792	1,546	1,295	1,039	768	496	220
Goodwill	965	965	965	965	965	965	965	965	965	965	965	965
Total assets	34,949	34,436	34,092	31,249	30,154	29,135	34,236	31,585	28,353	29,151	28,274	27,258
Accounts payable	2,610	4,499	7,681	7,767	6,201	6,985	6,048	5,314	4,409	5,385	5,753	6,650
Accrued liabilities	1,171	1,996	1,112	868	1,007	477	969	584	592	608	692	760
Total current liabilities	10,348	12,974	16,066	16,145	15,852	16,559	14,947	13,709	12,392	13,208	12,828	13,173
Lease liability, non-current	1,901	1,751	1,526	1,294	1,155	811	535	248	52	98	87	77
Total liabilities	22,885	24,914	27,604	27,003	27,531	27,038	27,384	25,526	23,672	24,229	23,542	23,619
Accumulated deficit	(76,082)	(79,042)	(82,506)	(85,185)	(87,118)	(88,009)	(89,695)	(90,689)	(92,262)	(92,446)	(92,970)	(94,236)
Total stockholders' equity	12,064	9,522	6,488	4,246	2,623	2,097	852	6,059	4,681	4,922	4,732	3,639
Total liabilities and equity	34,949	34,436	34,092	31,249	30,154	29,135	34,236	31,585	28,353	29,151	28,274	27,258
Common shares outstanding (cover page) thousands of shares	16,248	16,253	16,253	16,509	16,636	16,789	16,789	16,992	17,190	17,307	17,407	17,565

Cash flows

CSV

Fiscal quarters (IRIX's year ends in early January)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 30, 2023	Q1 FY24Mar 30, 2024	Q2 FY24Jun 29, 2024	Q3 FY24Sep 28, 2024	Q4 FY24Dec 28, 2024	Q1 FY25Mar 29, 2025	Q2 FY25Jun 28, 2025	Q3 FY25Sep 27, 2025	Q4 FY25Jan 3, 2026	Q1 FY26Apr 4, 2026	Q2 FY26Jul 4, 2026
Net income (loss)	(1,754)	(2,960)*	(3,464)	(2,679)	(1,933)	(834)*	(1,686)	(994)	(1,573)	(184)*	(524)	(1,266)
Net cash from operating activities	(1,782)*	(979)*	(1,648)	(1,326)*	(3,073)*	(1,238)*	(1,149)	(397)*	(1,158)*	589*	(1,335)	174*
Purchases of property and equipment	82*	(32)*	3	0*	1*	9*	11	13*	13*	106*	101	50*
Net cash from investing activities	(82)*	32*	(3)	0*	(1)*	(9)*	(11)	(13)*	(13)*	(106)*	(101)	(50)*
Net cash from financing activities	(24)*	45*	0	0*	2,823*	(218)*	6,039	(14)*	(34)*	(27)*	(1)	(38)*
Net change in cash	(1,840)*	(947)*	(1,615)	(1,308)*	(251)*	(1,473)*	4,857	(466)*	(1,205)*	455*	(1,433)	85*

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Nexalin Technology	1,005	12	(1,802)*	22.0M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
Mobia Medical	177,090	13,505	(15,670)*	33.3M	11.3 quarters	Q2 FY26 10-QJun 30, 2026
Beyond Air	5,509	1,768	(4,946)	957,631	2.0 quarters	Q1 FY27 10-QJun 30, 2026
RetinalGenix Technologies	27	not reported	(137)*	18.8M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Harvard Apparatus Regenerative Technology	351	414	(569)*	17.6M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.